Featured Research

from universities, journals, and other organizations

Study Shows Men With Erectile Dysfunction Favor Treatment With Vardenafil

Date:
September 24, 2006
Source:
Blackwell Publishing Ltd.
Summary:
Research published in the Journal of Sexual Medicine and presented at the 12th World Congress of the International Society for Sexual Medicine in Cairo, Egypt, is unique in that the data is from a head to head trial of PDE5 inhibitors used to treat patients with erectile dysfunction (ED), designed to minimize bias toward either study drug.

Research published in The Journal of Sexual Medicine and presented at the 12th World Congress of the International Society for Sexual Medicine in Cairo, Egypt is unique in that the data is from a head to head trial of PDE5 inhibitors used to treat patients with erectile dysfunction (ED), designed to minimize bias toward either study drug.

The study was a randomized, double-blind, crossover, head-to-head clinical trial that compared vardenafil and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results demonstrated that vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures, and non-inferiority of vardenafil to sildenafil as measured by various assessments of patient satisfaction and patient preference.

A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: "Overall, which medication do you prefer?" along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in analysis.

Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence.

"This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction," explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine.

There are currently three PDE5 inhibitors available to treat ED: sildenafil, tadalafil and vardenafil, all of which have previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers.

Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiate among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.

This study is published in The Journal of Sexual Medicine. The Journal of Sexual Medicine publishes multidisciplinary basic science and clinical research to define and understand the scientific basis of male and female sexual function and dysfunction. As the official journal of the International Society for Sexual Medicine, it provides healthcare professionals in sexual medicine with essential educational content and promotes the exchange of scientific information generated from experimental and clinical research. For more information visit: http://www.blackwellpublishing.com/jsm.


Story Source:

The above story is based on materials provided by Blackwell Publishing Ltd.. Note: Materials may be edited for content and length.


Cite This Page:

Blackwell Publishing Ltd.. "Study Shows Men With Erectile Dysfunction Favor Treatment With Vardenafil." ScienceDaily. ScienceDaily, 24 September 2006. <www.sciencedaily.com/releases/2006/09/060920191607.htm>.
Blackwell Publishing Ltd.. (2006, September 24). Study Shows Men With Erectile Dysfunction Favor Treatment With Vardenafil. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2006/09/060920191607.htm
Blackwell Publishing Ltd.. "Study Shows Men With Erectile Dysfunction Favor Treatment With Vardenafil." ScienceDaily. www.sciencedaily.com/releases/2006/09/060920191607.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins